TETANUS TOXOID ADSORBED Rx
Generic Name and Formulations:
Tetanus toxoid; aluminum adsorbed; susp for IM inj; multi-dose vial preserved with thimerosal, single-dose vials contain trace amounts of thimerosal.
Sanofi Pasteur, Inc.
Indications for TETANUS TOXOID ADSORBED:
Adults and Children:
<7yrs: not recommended. Give IM in anterolateral thigh or deltoid. ≥7yrs: Previously unvaccinated: three 0.5mL doses at elected date, then 4–8 weeks after first dose, and 6–12 months after second dose. Give booster dose at 11–12 yrs of age if last dose of tetanus and diphtheria toxoid-containing vaccine was given ≥5yrs ago. Other: give booster every 10 years.
Latex allergy. Previous arthus-type hypersensitivity reaction: do not give more frequently than every 10 years. Defer in moderate or severe active respiratory or other febrile infection (may vaccinate if mild or minor illness) or during polio outbreak. Guillain-Barre syndrome within 6 weeks of last tetanus vaccine. Bleeding disorders. Immunosuppressed. Have epinephrine (1:1000) available. Elderly. Pregnancy (Cat.C). Nursing mothers.
May get suboptimal response with immunosuppressants (eg, chemotherapy, high dose corticosteroids ≥2 weeks, radiation); consider deferring.
Local reactions (eg, erythema, tenderness), malaise, fever, hypotension, pain, nausea, arthralgia; rare: neurological disorders.
Single-dose vials (latex free)—10
Multi-dose vial (5mL)—1
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking